Hematology

City of Hope

City of Hope Tumor Board

Questions discussed in this category

How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?

7 Answers available

How would you treat an elderly male with history of mantle cell lymphoma who relapsed after chemoimmunotherapy and cBTKi w/ multiple co-morbidities including CKD and CHF w/ low EF?

1 Answer available

How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?

1 Answer available

How would you treat a patient who received 2 cycles of R-CHOP for DLBCL who was subsequently diagnosed with follicular lymphoma?

Would you continue R-CHOP or would you switch therapy?

1 Answer available

How would you treat an older patient with B symptoms and biopsy consistent with grade 3 follicular lymphoma but noted to have a PET scan with SUV readings of > 20?

1 Answer available

How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?

2 Answers available

How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?

2 Answers available

What is your preferred third-line therapy for a fit patient with symptomatic, relapsed follicular lymphoma who has failed bendamustine-rituximab and lenalidomide-rituximab?

2 Answers available

How would you manage a patient with NLPHL and CKD who relapsed after a long disease free interval (i.e. 7 years) following bendamustine?

1 Answer available

What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?

1 Answer available

How would you treat a BTKi naive p53 mutated MCL in 1st relapse with disease noted both systemically and in the CNS?

1 Answer available

How would you approach treatment for a R/R mantle cell lymphoma patient with a history of autoimmune hepatitis who has progressed on both a covalent and non-covalent BTKi?

1 Answer available

Would you recommend allogeneic stem cell transplantation for consolidation in a patient with follicular lymphoma who relapsed within 13 months of initial chemo-immunotherapy?

2 Answers available

Papers discussed in this category

Lancet Oncol, 2020 Jun 05

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.

Lancet Oncol, 2022 Jul 12

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.

J Clin Oncol, 2017 Jan 17

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

The Lancet. Oncology, 2011 Dec 13

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

American journal of hematology, 2016-09

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.

Blood, 2017 Jun 13

How I treat patients with aggressive lymphoma at high risk of CNS relapse.

JAMA, 2023 Aug 8

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.

Blood, 2017 Jan 31

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.

Blood, 2020 Apr 09

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study.

Hematology

City of Hope

Questions discussed in this category

Papers discussed in this category

Related Topics in Hematology